

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## 东曜药业

### TOT BIOPHARM International Company Limited

### 東曜藥業股份有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1875)**

### CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2022

This announcement is made by TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to applicable disclosure requirements of the Taipei Exchange in Taiwan, Center Laboratories Inc. (the Company’s controlling shareholder whose shares are listed on the Taipei Exchange in Taiwan) is required to disclose, on a date which is expected to be on or before 15 May 2022, certain unaudited consolidated financial information of the Group for the three months ended 31 March 2022.

In order to facilitate timely dissemination of information to investors and potential investors in Hong Kong and Taiwan, the Company’s board of directors (the “**Board**”) would like to inform the Company’s shareholders and potential investors of the following unaudited consolidated financial information of the Group for the three months ended 31 March 2022, which is extracted from the Group’s latest unaudited management accounts and other information currently available.

#### IMPORTANT

**As mentioned above, the Group’s results for the three months ended 31 March 2022 set out in this announcement are unaudited. The Group’s results of operations in the past have fluctuated and may in the future continue to fluctuate from one period to another period. Accordingly, the Group’s results of operations for any period should not be considered to be indicative of the results to be expected for any future period. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.**

**During the three months ended 31 March 2022, the Group’s revenue increased by 450.25% year-on-year to RMB80,249,000, mainly attributable to the substantial increase in the sales of the Group’s self-developed products and the increase in milestone payment income from the Group’s projects.**

## CONDENSED CONSOLIDATED BALANCE SHEET

	As at 31 March 2022 <i>RMB'000</i> (unaudited)	As at 31 December 2021 <i>RMB'000</i> (audited)
Current assets	371,405	305,963
Non-current assets	434,915	404,300
Current liabilities	(357,227)	(260,808)
Non-current liabilities	(112,915)	(114,364)
Total net assets	<u>336,178</u>	<u>335,091</u>

## CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS

	For the period from 1 January 2022 to 31 March 2022 <i>RMB'000</i> (unaudited)	For the period from 1 January 2021 to 31 March 2021 <i>RMB'000</i> (unaudited)
Revenue	80,249	14,584
Net loss	(4,713)	(42,715)
Other comprehensive income	304	387
Total comprehensive loss for the period	<u>(4,409)</u>	<u>(42,328)</u>

The above information is subject to possible adjustments following further internal review, and is not based on any figure(s) or information which has/have been reviewed by the Company's external auditor or the Audit and Connected Transactions Review Committee.

By order of the Board  
**TOT BIOPHARM International Company Limited**  
**Dr. Liu, Jun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 12 May 2022

*As at the date of this announcement, the executive directors of the Company are Dr. Liu, Jun and Ms. Yeh-Huang, Chun-Ying; the non-executive directors of the Company are Mr. Fu, Shan and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.*